
The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Safety and effectiveness for the treatment of partial-onset seizures in pediatric patients below the age of 1 month; adjunctive therapy for the treatment of myoclonic seizures in pediatric patients below the age of 12 years; and adjunctive therapy for the treatment of primary generalized tonic-clonic seizures in pediatric patients below the age of 6 years have not been established. Hematologic abnormalities occurred in clinical trials and included decreases in white blood cell WBC , neutrophil, and red blood cells counts RBC ; decreases in hemoglobin and hematocrit; and increases in eosinophil counts. There was no evidence of maternal toxicity. Last updated on Nov 1, It is freely soluble in chloroform Other than drowsiness, there were no adverse reactions in the few known cases of overdose in clinical trials. The dosing recommendation in these pediatric patients varies according to age group and is weight-based [see Dosage and Administration 2. The following adverse reactions are discussed in more details in other sections of labeling:. In controlled clinical studies using an oral formulation of KEPPRA in adult patients with partial-onset seizures, minor but statistically significant decreases compared to placebo in total mean RBC 0.